Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival

International Journal of Cancer

Volumn 119, Issue 5, 2006, Pages 980-984

  Gouin, François ^a,b,c,d   Ory, Benjamin ^a,b   Rédini, François ^a,b   Heymann, Dominique ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d Universite de Nantes   (France)

Author keywords

Adjuvant treatment; Bisphosphonate; Chondrosarcoma; Primary bone tumors; Therapy

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CASPASE 3; INTERLEUKIN 1BETA CONVERTING ENZYME; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE TUMOR; CANCER SURVIVAL; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CHONDROSARCOMA; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR RECURRENCE;

EID: 33746337357     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21951     Document Type: Article

References (42)

1. Lichtenstein L, Jaffe HL. Chondrosarcoma of bone. Am J Pathol 1942;19:553-74.
2. Dahlin DC, Unni KK. Bone tumors: general aspects and data on 8542 cases, 4th ed. Sprinfield, IL: Charles C Thomas, 1986.
3. Enneking WF. Musculoskeletal tumor surgery, vol. 2. New York: Churchill Livingstone, 1983. 875-997.
4. O'Neal LW, Ackerman LV. Chondrosarcoma of bone. Cancer 1952;5: 551-77.
5. Fiorenza F, Abudu A, Grimer RJ, Carter SR, Tillman RM, Ayoub K, Mangham DC, Davies AM. Risk factors for survival and local control in chondrosarcoma of bone. J Bone Joint Surg Br 2002;84:93-9.
6. Lee FY, Mankin HJ, Frondren G, Gebhardt MC, Springfield DS, Rosenberg AE, Jennings LC. Chondrosarcoma of bone: an assessment of outcome. J Bone Joint Surg Am 1999;81:326-38.
7. Pritchard DJ, Lunke RJ, Taylor WF, Dahlin DC, Medley BE. Chondrosarcoma: a clinicopathological and statistical analysis. Cancer 1980;45:149-57.
8. Donati D, El Ghoneimy A, Bertoni F, Di Bella C, Mercuri M. Surgical treatment and outcome of conventional pelvic chondosarcoma. J Bone Joint Surg Br 2005;87:1527-30.
9. Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 2000; 10:159-78.
10. Body J. Clinical research update: zoledronate. Cancer 1997;80:1699-1701.
11. Cheer S, Noble S. Zoledronic acid. Drugs 2001;61:799-805.
12. Gatti D, Adami S. New bisphosphonates in the treatment of bone diseases. Drugs Aging 1999;15:285-96.
13. Pataki A, Muller K, Green J, Ma Y, Li Q, Jee W. Effects of short-term treatment with the bisphosphonate zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during, and after treatment. Anat Rec 1997; 249:458-68.
14. Benford HL, McGowan NWA, Helfrich MH, Nuttall M, Roger MJ. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 2001;28:465-73.
15. Berenson J, Rosen L, Howell A, Porter L, Coleman R, Morley W, Dreicer R, Kuross S, Lipton A, Seaman J. Zoledronic acid reduces skeletal-related events in patients with osteolytic lesions. Cancer 2001;91:1191-1200.
16. Lipton A. Bisphosphonates and breast carcinoma. Cancer 2000;8:3033-7.
17. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M. Zoledronic acid prostate cancer study group. Long term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96:879-82.
18. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 2003;2:3150-7.
19. Jagdev SP, Coleman RE, Shipman CM, Rostami -HA, Croucher PI. The bisphosphonate zoledronic acid induced apoptosis of breat cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001;84: 1126-34.
20. Mackie PS, Fisher JL, Zhou H, Choong PF. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer 2001;84:951-8.
21. Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, Van Valen F. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 2001; 12:459-65.
22. Evdokiou A, Labrinidis A, Bouralexis S, Hay S, Findlay DM. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone 2003;33:216-28.
23. Heymann D, Ory B, Blanchard F, Heymann MF, Coipeau P, Charrier C, Couillaud S, Thiery JP, Gouin F, Redini F. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone 2005;37:74-86.
24. Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Redini F. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 2005;104:2522-31.
25. Guerne PA, Lotz M. Interleukin-6 and transforming growth factor-b synergistically stimulate chondrosarcoma cell proliferation. J Cell Physiol 1991;149:117-24.
26. Grimaud E, Damiens C, Rousselle AV, Passuti N, Heymann D, Gouin F. Bone remodelling and tumor grade modifications induced by interactions between bone and swarm rat chondrosarcoma. Histol Histopathol 2002; 17:1103-11.
27. Gitelis S, Bertoni F, Picci P, Campannacci M. Chondrosarcoma of bone. The experience at the Institute Ortopedico Rizzoli. J Bone Joint Surg Am 1981;63:1248-57.
28. Sheth DS, Yasko AW, Johnson ME, Ayala AG, Murray JA, Romsdahl MM. Chondrosarcoma of the pelvis. Prognostic factors for 67 patients treated with definitive surgery. Cancer 1996;78: 745-50.
29. Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer 1977;40:818-31.
30. Springfield DS, Gebhardt MC, McGuire MH. Chondrosarcoma: a review. Instr Course Lect 1996;45:417-24.
31. Anract P, Tomeno B, Forest M. Dedifferentiated chondrosarcoma. A study of 13 clinical cases and review of the literature. Rev Chir Orthop Reparatrice Appar Mot 1994;80:669-80.
32. Capanna R, Bertoni F, Betteli G, Picca P, Bacchini P, Present D, Guinti A, Campanacci M. Dedifferentiated chondrosarcoma. J Bone Joint Surg Am 1988;70:60-9.
33. Frassica FJ, Unni KK, Beabout JW, Sim FH. Dedifferentiated chondrosarcoma. A report of the clinico-pathological features and treatment of seventy-eight cases. J Bone Joint Surg Am 1986;68:1197-205.
34. Mittermayer F, Dominkus M, Krepler P, Schwameis E, Sluga M, Toma C, Lang S, Grampp S, Kotz R. Chondrosarcoma of the hand: is a wide surgical resection necessary? Clin Orthop Relat Res 2004; 424:211-5.
35. Van Der Geest IC, Servaes P, Schreuder HW, Bleijenberg G, Verhagen CA, Pruszczynski M, Lemmens JA, Veth RP. Chondrosarcoma of bone: functional outcome and quality of life. J Surg Oncol 2002; 81:70-4.
36. Veth R, Schreuder B, van Beem H, Pruszczynski M, de Rooy J. Cryo-surgery in aggressive, benign, an low-grade malignant bone tumors. Lancet Oncol 2005;6:25-34.
37. Streibuerger A, Hardes J, Ahrens H, Gebert C, Boos J, Winkelmann W, Gosheger G. In vitro trial: cytotoxic effect of bisphosphonates on the chondrosarcoma cell line CAL 78. In: Eighteenth annual meeting of european musculoskeletal oncology society, Trieste, Italy, 2005. C24.
38. Breitkreutz D, Diaz de Leon L, Paglia L, Gay S, Swarm RL, Stern R. Histological and biochemical studies of a transplantable rat chondrosarcoma. Cancer Res 1979;39:5093-5100.
39. Kenan S, Steiner GC. Experimental transplantation of the swarm rat chondrosarcoma into bone: radiological and pathological studies. J Orthop Res 1991;9:445-51.
40. Heymann D, Ory B, Gouin F, Green JR, Redini F. Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends Mol Med 2004;10:337-43.
41. Sietsema WK. Antiresorptive dose-response relations across three generations of bisphosphonates. Drugs Exp Clin Res 1989;15:389-96.
42. Skerjanec A, Berenson J, Hsu C, Major P, Miller WH, Jr, Ravera C, Schran H, Seaman J, Waldmeier F. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patient with varying degrees of renal function. J Clin Pharmacol 2003;43:154-62.